Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis
暂无分享,去创建一个
M. Gurney | C. Epstein | T. Siddique | S. Przedborski | H. Deng | V. Kostic | V. Kostić
[1] R. Sidman,et al. Atlas of the Mouse Brain and Spinal Cord , 1971 .
[2] L. Kurland,et al. Familial amyotrophic lateral sclerosis. A subgroup characterized by posterior and spinocerebellar tract involvement and hyaline inclusions in the anterior horn cells. , 1967, Archives of neurology.
[3] M. Pericak-Vance,et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. , 1993, Science.
[4] D. Borchelt,et al. Superoxide dismutase is an abundant component in cell bodies, dendrites, and axons of motor neurons and in a subset of other neurons. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[5] C. Marsden,et al. Sequence of the superoxide dismutase 1 (SOD 1) gene in familial Parkinson's disease. , 1995, Journal of neurology, neurosurgery, and psychiatry.
[6] S. Varon,et al. Ciliary neurotrophic factor prevents degeneration of adult rat substantia nigra dopaminergic neurons in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[7] H. Hayashi,et al. Amyotrophic lateral sclerosis patients living beyond respiratory failure , 1991, Journal of the Neurological Sciences.
[8] O. Elroy-Stein,et al. Cell damage by excess CuZnSOD and Down's syndrome. , 1994, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[9] A. Björklund,et al. Brain-derived neurotrophic factor enhances function rather than survival of intrastriatal dopamine cell-rich grafts , 1993, Brain Research.
[10] R. Marttila,et al. Oxygen toxicity protecting enzymes in Parkinson's disease Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus , 1988, Journal of the Neurological Sciences.
[11] M. Lovett,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity: animal model of dosage effects in Down syndrome. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[12] W. Engel,et al. Amyotrophic lateral sclerosis: metabolism of central monoamines and treatment with L-dopa. , 1971, Transactions of the American Neurological Association.
[13] R. Coggeshall,et al. Methods for determining numbers of cells and synapses: A case for more uniform standards of review , 1996, The Journal of comparative neurology.
[14] D. Reis,et al. Genetic control of number of midbrain dopaminergic neurons in inbred strains of mice: relationship to size and neuronal density of the striatum. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[15] J. Haines,et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis , 1993, Nature.
[16] G. Rosoklija,et al. Brain superoxide dismutase, catalase, and glutathione peroxidase activities in amyotrophic lateral sclerosis , 1996, Annals of neurology.
[17] D. Bredesen,et al. Altered Reactivity of Superoxide Dismutase in Familial Amyotrophic Lateral Sclerosis , 1996, Science.
[18] C. Epstein,et al. 3‐Nitropropionic Acid Neurotoxicity Is Attenuated in Copper/Zinc Superoxide Dismutase Transgenic Mice , 1995, Journal of neurochemistry.
[19] C. Marsden,et al. A Selective Increase in Particulate Superoxide Dismutase Activity in Parkinsonian Substantia Nigra , 1989, Journal of neurochemistry.
[20] D. Togasaki,et al. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by instrastriatal injection of 6-hydroxydopamine , 1995, Neuroscience.
[21] M. Gurney,et al. Age-Dependent Penetrance of Disease in a Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis , 1995, Molecular and Cellular Neuroscience.
[22] C. Epstein,et al. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[23] D. Borchelt,et al. Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. Gurney,et al. Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis , 1996, Annals of neurology.
[25] V. Dhawan,et al. Nigrostriatal dopaminergic function in familial amyotrophic lateral sclerosis patients with and without copper/zinc superoxide dismutase mutations , 1996, Neurology.
[26] C. Epstein,et al. Increased Superoxide Dismutase Activity Improves Survival of Cultured Postnatal Midbrain Neurons , 1996, Journal of neurochemistry.
[27] M. Beal,et al. Motor neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury , 1996, Nature Genetics.
[28] S. Fahn,et al. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it , 1992, Annals of neurology.
[29] M. Oda,et al. Diminution of dopaminergic neurons in the substantia nigra of sporadic amyotrophic lateral sclerosis , 1993, Neuropathology and applied neurobiology.
[30] M. Gurney,et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.
[31] L. Rowland. Amyotrophic lateral sclerosis: human challenge for neuroscience. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[32] T. Dawson,et al. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.